华检医疗(01931)发布公告，于2025年9月16日斥资1305.64万港元回购121.1万股。 ...

智通财经APP讯，华检医疗(01931)发布公告，于2025年9月16日斥资1305.64万港元回购121.1万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 不適用 第一章節註釋： 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年9月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - The company, Huajian Medical, is undergoing a strategic transformation by establishing two joint ventures with ETHK Group to deepen its global blockchain financial ecosystem, focusing on asset tokenization, including "on-chain stocks" [1][8]. Group 1: Company Developments - On September 14, Huajian Medical announced the establishment of ETHK Inc. and ETHK HOLDINGS LIMITED to enhance its blockchain financial strategy [1]. - The company plans to change its English name to "ETHK Labs Inc." and its Chinese name to "华检数字产业集团有限公司" to reflect its ambition in digital industry innovation [1]. - Following the announcements, Huajian Medical's stock price surged approximately 8%, closing at HKD 10.71, a significant increase from HKD 2.22 on July 2 [2]. Group 2: Industry Trends - Asset tokenization is emerging as a major trend in global financial markets, exemplified by Galaxy Digital's recent partnership to allow shareholders to tokenize and hold GLXY stocks on-chain [5]. - The advantages of on-chain stocks include 24/7 trading, near-instant settlement, reduced transaction costs, and global accessibility, driving a revolution in traditional financial assets [5][13]. - A joint prediction by BCG and ADDX estimates that the global Real World Asset (RWA) market will reach USD 16.1 trillion by 2030, accounting for 10% of global GDP [6]. Group 3: Strategic Value - Huajian Medical's strategic upgrade aims to create a comprehensive "ETHK" blockchain financial ecosystem, focusing on five core pillars: technical infrastructure, financial product matrix, sustainable models, global compliance framework, and seamless user access [8][11]. - The company's vision aligns with national policies promoting financial technology innovation and digital economy development, providing new channels for global financing and circulation of quality Chinese assets [12]. - The on-chain stock tokenization model could revolutionize financing for capital-intensive industries, breaking traditional geographical and temporal limitations for global investors [12].

Core Viewpoint - The company Huajian Medical (01931) is undergoing a strategic transformation by establishing two new companies in collaboration with ETHK Group, focusing on the tokenization of equity assets and the development of a global blockchain financial ecosystem [1][6]. Group 1: Company Developments - Huajian Medical announced the formation of ETHK Inc. and ETHK HOLDINGS LIMITED to enhance its global blockchain financial strategy, particularly in promoting "on-chain stocks" [1]. - The company plans to change its English name to "ETHK Labs Inc." and its Chinese name to "华检数字产业集团有限公司" to reflect its ambition to become a leader in digital industry innovation and blockchain technology [1]. - Following the announcement, Huajian Medical's stock price surged approximately 8%, closing at HKD 10.71, a significant increase from HKD 2.22 on July 2 [1]. Group 2: Industry Trends - Asset tokenization is emerging as a significant trend in global financial markets, with Galaxy Digital recently allowing shareholders to tokenize and hold GLXY stocks on-chain, marking a notable case of stock tokenization by a public company [4]. - The advantages of on-chain stocks include 24/7 trading, near-instant settlement, reduced transaction costs, and seamless global circulation, driving a revolution in traditional financial assets [4]. - A joint prediction by Boston Consulting Group and ADDX estimates that by 2030, the global Real World Asset (RWA) market will reach USD 16.1 trillion, accounting for 10% of global GDP [4]. Group 3: Strategic Vision - The strategic upgrade of Huajian Medical aims to systematically build the "ETHK" blockchain financial ecosystem, which includes five core pillars: technical infrastructure, financial product matrix, sustainable models, global compliance framework, and seamless user access [6][9]. - The establishment of the two joint ventures allows Huajian Medical to focus on technology platform development while integrating global quality resources through capital means, creating a self-sustaining growth model [9]. - The company's vision aligns with national policies promoting financial technology innovation and digital economic development, potentially providing new channels for global financing and circulation of high-quality Chinese assets [10].

Core Viewpoint - The announcement by Huajian Medical (01931.HK) regarding the establishment of joint ventures and a rebranding signifies a strategic shift towards "on-chain finance," aiming to build the next generation of global asset circulation infrastructure [1][3]. Group 1: Strategic Shift - The name change from "IVD Medical Holding Limited" to "ETHK Labs Inc." reflects a new strategic vision that aligns with its role as a key technology and infrastructure provider in the "ETHK on-chain financial ecosystem" [1][3]. - The establishment of joint ventures alongside the rebranding indicates a systematic increase in investment in digital industries and on-chain finance, suggesting a long-term commitment rather than short-term market speculation [3]. Group 2: Trust Mechanism - There are two contrasting perspectives on Huajian Medical's transformation: supporters believe blockchain can effectively address global asset liquidity issues, while skeptics question the scalability of RWA (Real World Asset) and the clarity of the business model [4][6]. - The ability to build a sustainable, regulatory-compliant, and scalable trust system is crucial for the success of Huajian Medical's strategy [6]. Group 3: Strategic Drivers - The transformation is driven by three factors: the need to overcome growth bottlenecks in existing business, the necessity to attract investor attention with a new global and tech-oriented narrative, and the supportive policy environment in Hong Kong for Web3 and digital asset innovation [8]. Group 4: Value Distribution - Huajian Medical's ETHK ecosystem aims to create new opportunities for asset owners by providing pathways for financing and global market access through on-chain tools [9]. - For capital providers, Huajian Medical is expected to offer new investment interfaces that connect them to high-quality assets traditionally overlooked by the financial system [9]. Group 5: Conclusion - The establishment of joint ventures and the rebranding highlight a significant trend where Chinese quality assets are attempting to achieve global circulation through blockchain technology, while global capital seeks new value anchors [11]. - The success of Huajian Medical in converting its narrative of "on-chain finance" into a credible, investable, and sustainable reality will depend on its ability to address technical implementation, compliance, business models, and ecosystem collaboration [11][12].

Group 1 - The core viewpoint of the news is the strategic partnership between Huajian Medical and Renhe Pharmaceutical's subsidiary to establish the world's first OTC-focused RWA exchange in the U.S. [1] - This collaboration is a key step in Huajian Medical's "ETHK blockchain financial ecosystem strategy" and aims to create a replicable model to validate the feasibility and potential of this innovative approach [1][2] - Huajian Medical will provide compliance operational support through ETHK Inc, while Huajian Digital Industry Development (Shenzhen) Co., Ltd. will handle technology development [1] Group 2 - Renhe Pharmaceutical, a leading player in China's OTC market, aims to revitalize its brand and intangible assets through this partnership, especially after facing revenue declines of 16.46% and net profit drops of 13.87% in the first half of the year [1] - The collaboration is expected to generate significant technical service revenue for Huajian Medical and validate its light-asset, replicable empowerment model [2] - The "ETHK global RWA exchange" model is designed to connect the industry and financial sectors, providing asset selection, structural design, compliance issuance, and liquidity management services [2]

Core Viewpoint - Hong Kong-listed Huajian Medical experienced a recovery in share price after a significant drop of over 10% in the morning session, following the announcement of a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1] Group 1 - Huajian Medical's share price fell more than 10% in the morning session before turning positive in the afternoon [1] - The company announced a strategic cooperation with Renhe International to develop a vertical RWA exchange for OTC drugs in the U.S. [1] - This partnership aims to create a dedicated platform for the OTC drug market, indicating a significant move within the pharmaceutical industry [1]

Group 1 - The core viewpoint of the news is that Huajian Medical and Renhe Pharmaceutical have established a strategic partnership to create the world's first specialized trading platform for Real World Assets (RWA) in the over-the-counter (OTC) drug sector [1][2] - The platform will adhere to securities-level standards and aims to provide an efficient, transparent, and compliant digital trading venue for intangible assets such as intellectual property, future revenue rights, and brand value in the OTC industry [1][2] - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a significant role in industry policy discussions and standard-setting, leveraging its competitive position in the Chinese OTC market to lead industry development [1][2] Group 2 - This strategic cooperation marks a new phase for the "ETHK" blockchain financial ecosystem strategy, showcasing the innovative "ETHK Global RWA Trading Exchange" business model on a global stage [2] - The collaboration reflects the company's commitment to creating a truly open and empowering digital financial ecosystem through cutting-edge technology and rigorous compliance practices [2] - The ultimate mission of financial technology is to serve the real economy and create inclusive value, with the partnership exemplifying this belief [2] Group 3 - The board believes that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [3] - The collaboration aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange by pooling the strengths and resources of both parties [3] - The partnership is expected to inject strong momentum into the sustainable business growth and financial performance of the group [3]

Core Viewpoint - Huajian Medical (01931) has announced a strategic partnership with Renhe Pharmaceutical (000650.SZ) to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in the implementation of its "ETHK blockchain financial ecosystem strategy" [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical signifies a new phase in the large-scale implementation and value realization of the "ETHK" blockchain financial ecosystem strategy [1] - This partnership serves as a benchmark case for the innovative "ETHK global RWA exchange" business model, aiming to create a replicable model that validates the feasibility and potential of this innovation [1] Group 2: Vision and Mission - The company believes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The goal is to empower classic national brands like Renhe Pharmaceutical to achieve digital transformation and promote successful ecological models across various industries, contributing to national industrial upgrades and the development of the digital economy [2] Group 3: Future Outlook - The board is confident that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - The company aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange through close collaboration with Renhe Pharmaceutical, leveraging both parties' resources [2]